Reviewing BioRestorative Therapies (NASDAQ:BRTX) & Mangoceuticals (NASDAQ:MGRX)

BioRestorative Therapies (NASDAQ:BRTX) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Insider & Institutional Ownership

6.9% of BioRestorative Therapies shares are held by institutional investors. Comparatively, 0.0% of Mangoceuticals shares are held by institutional investors. 21.6% of BioRestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioRestorative Therapies and Mangoceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioRestorative Therapies	0	0	0	0	N/A
Mangoceuticals	0	0	0	0	N/A

Earnings and Valuation

This table compares BioRestorative Therapies and Mangoceuticals’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioRestorative Therapies	$120,000.00	77.06	-$18.50 million	N/A	N/A
Mangoceuticals	$250,898.00	41.97	-$2.00 million	N/A	N/A

Mangoceuticals has higher revenue and earnings than BioRestorative Therapies.

Profitability

This table compares BioRestorative Therapies and Mangoceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioRestorative Therapies	-13,728.83%	-120.47%	-114.48%
Mangoceuticals	N/A	N/A	N/A

Summary

Mangoceuticals beats BioRestorative Therapies on 5 of the 8 factors compared between the two stocks.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

About Mangoceuticals

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.